Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
The domestic business has registered a single-digit growth on the huge base of last year and this was driven by robust demand across established therapies and brands
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
Ministry of Ayush signed a MoU with Ministry of Micro, Small & Medium Enterprises (MSME) for the promotion of Ayush enterprises.
Ministry of Ayush has fast tracked up-gradation and construction of various Ayush Infrastructure across the country
The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.
Under the PMBJP, till 30.06.2022, 8742 PMBJKs have been opened across the country including Government Hospitals and Government premises.
Subscribe To Our Newsletter & Stay Updated
